Brief: Aeon Biopharma Announces Positive Outcome From FDA Biosimilar Advisory Meeting
30/09/2024 13:13
Sept 30 (Reuters) - Aeon Biopharma Inc AEON.A :
* AEON BIOPHARMA ANNOUNCES POSITIVE OUTCOME FROM FDA
BIOSIMILAR
ADVISORY MEETING
* AEON BIOPHARMA INC - COMPARATIVE ANALYTICAL STUDIES
ANTICIPATED
TO COMMENCE IN Q4 2024
* AEON BIOPHARMA INC - EXPECT TO CONDUCT A BIOSIMILAR
BIOLOGICAL
PRODUCT DEVELOPMENT (BPD) TYPE 2 MEETING WITH FDA IN 2025
* AEON BIOPHARMA INC - BPD TYPE 2 MEETING WITH FDA IN 2025
TO
REVIEW RESULTS FROM ANALYTICAL STUDIES AND CONFIRM REMAINDER OF
PROPOSED STUDY PACKAGE
Source text for Eikon: urn:newsml:reuters.com:*:nGNX915d8J
Further company coverage: AEON.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition